Provectus Biopharmaceuticals, Inc.
PVCT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 10.7% | -43.6% | – | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 98.8% | -204.8% | 93.6% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -733.2% | -518.5% | -340.1% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -766.9% | -556.2% | -359.3% | – |
| EPS Diluted | -0.011 | -0.007 | -0.009 | -0.016 |
| % Growth | -52.7% | 12.9% | 46.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |